Clinical Cancer Research, Vol 1, Issue 10 1089-1094, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion

MM Webber, A Waghray and D Bello
Departments of Medicine and Zoology, Michigan State University, East Lansing, Michigan 48824-1312, USA.

Human prostatic epithelial cells constitutively secrete prostate-specific antigen (PSA), a kallikrein-like serine protease, which is a normal component of the seminal plasma. PSA is currently used as a specific diagnostic marker for the early detection of prostate cancer. We demonstrate that PSA degrades extracellular matrix glycoproteins fibronectin and laminin and, thus, may facilitate invasion by prostate cancer cells. Blocking PSA proteolytic activity with PSA-specific mAb results in a dose-dependent decrease in vitro in the invasion of the reconstituted basement membrane Matrigel by LNCaP human prostate carcinoma cells which secrete high levels of PSA. A novel PSA-SDS-PAGE zymography method for the detection of matrix degrading ability of PSA is also described. We propose that: (a) because of the dysplastic cellular disorganization in early neoplastic lesions called prostatic intraepithelial neoplasia (PIN), PSA may be secreted not only at the luminal end but also, abnormally, at the cell-basement membrane interface, causing matrix degradation and facilitating invasion; and (b) PSA, along with urokinase, another serine protease secreted by prostatic epithelium, may be involved in the proteolytic cascade during prostate cancer invasion and metastasis. The discovery of the extracellular matrix degrading ability of PSA not only makes it a marker for early detection but also a target for prevention and intervention in prostate cancer.

This article has been cited by other articles:

				Y. Niu, S. Yeh, H. Miyamoto, G. Li, S. Altuwaijri, J. Yuan, R. Han, T. Ma, H.-C. Kuo, and C. Chang Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation Cancer Res., September 1, 2008; 68(17): 7110 - 7119. [Abstract] [Full Text] [PDF]

				K. Horii, Y. Suzuki, Y. Kondo, M. Akimoto, T. Nishimura, Y. Yamabe, M. Sakaue, T. Sano, T. Kitagawa, S. Himeno, et al. Androgen-Dependent Gene Expression of Prostate-Specific Antigen Is Enhanced Synergistically by Hypoxia in Human Prostate Cancer Cells Mol. Cancer Res., April 1, 2007; 5(4): 383 - 391. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]

				S. D. Cho, C. Jiang, B. Malewicz, Y. Dong, C. Y.F. Young, K.-S. Kang, Y.-S. Lee, C. Ip, and J. Lu Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription Mol. Cancer Ther., May 1, 2004; 3(5): 605 - 612. [Abstract] [Full Text] [PDF]

				M. T. Gallardo-Williams, R. E. Chapin, P. E. King, G. J. Moser, T. L. Goldsworthy, J. P. Morrison, and R. R. Maronpot Boron Supplementation Inhibits the Growth and Local Expression of IGF-1 in Human Prostate Adenocarcinoma (LNCaP) Tumors in Nude Mice Toxicol Pathol, January 1, 2004; 32(1): 73 - 78. [Abstract] [PDF]

				H. T. Le, C. M. Schaldach, G. L. Firestone, and L. F. Bjeldanes Plant-derived 3,3'-Diindolylmethane Is a Strong Androgen Antagonist in Human Prostate Cancer Cells J. Biol. Chem., May 30, 2003; 278(23): 21136 - 21145. [Abstract] [Full Text] [PDF]

				S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]

				Y. Dong, A. Kaushal, L. Bui, S. Chu, P. J. Fuller, J. Nicklin, H. Samaratunga, and J. A. Clements Human Kallikrein 4 (KLK4) Is Highly Expressed in Serous Ovarian Carcinomas Clin. Cancer Res., August 1, 2001; 7(8): 2363 - 2371. [Abstract] [Full Text] [PDF]

				G. M. Yousef and E. P. Diamandis The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease Endocr. Rev., April 1, 2001; 22(2): 184 - 204. [Abstract] [Full Text]

				E. P. Diamandis Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger? Clin. Chem., July 1, 2000; 46(7): 896 - 900. [Abstract] [Full Text] [PDF]

				M. H. Black, M. Giai, R. Ponzone, P. Sismondi, H. Yu, and E. P. Diamandis Serum Total and Free Prostate-specific Antigen for Breast Cancer Diagnosis in Women Clin. Cancer Res., February 1, 2000; 6(2): 467 - 473. [Abstract] [Full Text]

				B. Lin, C. Ferguson, J. T. White, S. Wang, R. Vessella, L. D. True, L. Hood, and P. S. Nelson Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS2 Cancer Res., September 1, 1999; 59(17): 4180 - 4184. [Abstract] [Full Text] [PDF]

				C. S. Chan, M. B. Harvey, and J. A. Clements Temporal and Tissue-Specific Expression of Kallikrein (Klk) Genes and Identification of a Novel Klk Messenger Ribonucleic Acid Transcript during Early Development in the Mouse Biol Reprod, September 1, 1999; 61(3): 621 - 628. [Abstract] [Full Text]